Brain Neurons
Targeted Science. Transforming Parkinson’s
Contact Us

Preclinical Biotechnology Company

We are the leading preclinical biotechnology company developing first-in-class small-molecule therapies for Parkinson’s disease. Our lead program targets the G2019S mutation in the LRRK2 gene using a highly selective inhibitor to slow disease progression. Based in New York, we collaborate with Vanderbilt University and the Michael J. Fox Foundation and are preparing for IND-enabling studies in 2025. Reach out to our preclinical team to learn more about our translational research and targeted therapeutic approach.

G2019S-Selective LRRK2 Inhibitor (Lead Product)

Our lead program is a first-in-class, highly selective small-molecule inhibitor targeting the G2019S mutation in LRRK2, the most common genetic cause of Parkinson’s disease. It provides a disease-modifying mechanism with superior safety and brain penetration by sparing wild-type LRRK2.

Precision Medicine Approach for Genetic Parkinson’s

We are pioneering a precision neurology platform using biomarker-driven patient stratification with mutation-targeted therapeutics. This approach enables more effective treatment and better clinical trial outcomes for genetically defined PD populations.

Biomarker-Driven Drug Development Platform

Our approach combines validated CNS and biofluid biomarkers (e.g., pS935-LRRK2, Rab10, BMP, and CSF LRRK2) to assess target engagement, patient selection, and clinical progress, establishing a scalable foundation for future Parkinson's disease programs.

About

Kifa Therapeutics is a precision neuroscience company developing first-in-class therapies for genetically defined Parkinson’s disease. Our lead program targets the G2019S mutation in LRRK2—the most common genetic driver of familial PD—with unmatched selectivity, brain penetration, and translational promise. Our discovery platform is grounded in the work of Dr. Craig Lindsley, Executive Director of the Warren Center for Neuroscience Drug Discovery at Vanderbilt University. A leader in medicinal chemistry with over 500 publications and 100+ patents, Dr. Lindsley brings deep expertise in advancing academic innovation into clinical candidates. Supported by the Michael J. Fox Foundation and a leadership team with decades of CNS drug development experience, Kifa is pioneering a precision medicine approach to deliver disease-modifying treatments for Parkinson’s and beyond. Contact us to learn more about our research and team.

“Proud member of The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) Consortium, a collaborative effort to advance LRRK2-targeted therapeutics for Parkinson’s disease.”

Request more information about our research

Contact Us